LOS ANGELES, July 21, 2016 /PRNewswire/ -- StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Jim Caruso, President & CEO of Cellectar Biosciences, Inc. (NASDAQ: CLRB), developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells, according to the Company's website (see here: www.CellectarBiosciences.com). The video interview was recorded on Thursday, June 2nd, 2016 at the Marcum MicroCap Conference in New York City, NY.
Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC Delivery Platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is actively developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For additional information please visit www.cellectarbiosciences.com
StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.
Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stocknewsnowcom-publishes-new-snnlive-video-interview-with-cellectar-biosciences-inc-discussing-corporate-updates-and-clinical-development-300301935.html